DMPK Strategies in the Preclinical Development of Antibody-Drug Conjugates

Webinar Overview

Antibody-drug conjugates (ADCs) stand out as innovative biotherapeutics, composed of cytotoxic payloads conjugated to antibodies through chemical linkers. ADCs present a complex landscape for understanding their ADME (adsorption, distribution, metabolism, and excretion) properties during the discovery and development stages. The efficacy of ADCs depends on the precise release and concentration of the payload in target tissues, while minimizing toxicity requires preventing off-target release in non-target tissues. Navigating this complexity demands a dual approach, integrating small molecule bioanalysis and large molecule bioanalysis platforms for comprehensive pharmacokinetic studies.

Our webinar, "DMPK Strategies in the Development of Antibody-Drug Conjugates," is designed to provide you with a strategic pharmacokinetic study plan tailored to the diverse structures of ADC projects. Throughout the webinar, we will cover challenging yet essential aspects of investigating ADCs such as payload release, catabolite identification in multiple in vitro systems, drug–antibody ratio (DAR) detection, and integrated bioanalysis platform for both small and large molecules.

Webinar presenter 

Liping Ma

Dr. Liping Ma, Ph.D. of Pharmaceutical Analysis, an expert in ADC pharmacokinetic evaluation, is now a senior study director in DMPK Service Department of WuXi AppTec. She has over 10 years of research experience in the field of preclinical and clinical pharmacokinetics and extensive experience in the preclinical development of new modality drugs. She successfully supported over 20 new drug IND applications globally.